ASCO 2022

ASCO 2022
June 03-07, 2022
Chicago, IL

American Society of Clinical Oncology 2022.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (8)

    Sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study

    • Author(s): Bardia, A
    • trodelvy
    • Oncology

    Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline TP53m AML patients: Phase 1b results

    • Author(s): Daver, N
    • magrolimab
    • Oncology

    Impact of magrolimab treatment in combination with azacitidine on red blood cells in higher-risk myelodysplastic syndrome (HR-MDS) patients

    • Author(s): Chen, J
    • magrolimab
    • Oncology

    Magrolimab in combination with azacitidine for untreated higher-risk myelodysplastic syndromes (HR-MDS): 5F9005 Phase 1b study results

    • Author(s): Sallman, D_
    • magrolimab
    • Oncology

    Primary Results From TROPiCS-02: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Treatment of Physician’s Choice (TPC) in Patients With Hormone Receptor-Positive/HER2-Negative (HR+/HER2-) Advanced Breast Cancer

    • Author(s): Rugo, H, A
    • trodelvy
    • Oncology

    Exposure-Response Analyses of Sacituzumab Govitecan (SG) Efficacy and Safety in Patients (Pts) With Metastatic Triple-Negative Breast Cancer (mTNBC)

    • Author(s): Singh, I
    • trodelvy
    • Oncology

    Trial in Progress: EVOKE-02: A phase 2 study of sacituzumab govitecan plus pembrolizumab (pembro) with or without platinum chemotherapy in first-line metastatic non−small-cell lung cancer (NSCLC)

    • Author(s): Garon, E
    • trodelvy
    • Oncology

    Trial in Progress: EVOKE-01: A phase 3 study of sacituzumab govitecan (SG) vs docetaxel in patients with non-small cell lung cancer (NSCLC) progressing on or after platinum-based chemotherapy and checkpoint inhibitors

    • Author(s): Garassino, M
    • trodelvy
    • Oncology